Mereo BioPharma Group PLC ADR

Yahoo Finance • 4 hours ago

DigitalBridge downgraded, Commvault initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Claim 70% Off TipRanks This Holiday Season Unlock hedge... Full story

Yahoo Finance • 21 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at new... Full story

Yahoo Finance • yesterday

DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrade: Argus upgraded BHP Group (BHP) to Buy fro... Full story

Yahoo Finance • 12 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Slightly Higher for Week

European equities traded in the US as American depositary receipts were rising late Friday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 27 days ago

Mereo BioPharma Group And 2 Undervalued Penny Stocks To Watch

Major U.S. stock indexes recently closed higher, with the Dow Jones Industrial Average adding 400 points as investors shrugged off a decline in private employment figures. In this context, penny stocks—often associated with smaller or newe... Full story

Yahoo Finance • 4 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at ne... Full story

Yahoo Finance • 4 months ago

3 Promising Penny Stocks With Market Caps Under $2B

As the Dow Jones Industrial Average reaches an all-time high, investors are keenly watching for opportunities amid mixed performances in major indices. In this context, penny stocks—often representing smaller or newer companies—remain a co... Full story

Yahoo Finance • 5 months ago

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE... Full story

Yahoo Finance • 5 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at ne... Full story

Yahoo Finance • 6 months ago

Ultragenyx and Mereo to continue Phase 3 trials of OI treatment to completion

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) announced Wednesday that their Phase 3 trials evaluating UX143 (setrusumab) for osteogenesis imperfecta (OI) will continue to final a... Full story

Yahoo Finance • 6 months ago

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study eval... Full story

Yahoo Finance • 8 months ago

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group pl... Full story

Yahoo Finance • 9 months ago

Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Mereo BioPharma Group (NASDAQ:MREO) stands against other biotech penny stocks. Peter M... Full story

Yahoo Finance • 9 months ago

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-as... Full story

Yahoo Finance • 10 months ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Exec... Full story

Yahoo Finance • 2 years ago

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments a... Full story

Yahoo Finance • 2 years ago

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day... Full story

Yahoo Finance • 2 years ago

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented... Full story

Yahoo Finance • 2 years ago

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif., July 06, 2023 (GLO... Full story

Yahoo Finance • 3 years ago

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing... Full story